Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream
Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc.
Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025
Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate
Regen BioPharma Explores Expanded Use of HemaXellerate for Chemotherapy-Induced Bone Marrow Suppression
Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market
Regen BioPharma, Inc. to Seek Orphan Drug Designation for Lead Product
Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 25, 2024, At 4 pm Eastern Time
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
